The Cocktail Report (sound really smart around your friends):
APOE4, the gene variant that most raises Alzheimer's risk, converts pericytes, the cells that stabilize small blood vessels, into scar-forming cells.
The scarring thickens vessel walls and drives amyloid buildup around them, the same protein target current Alzheimer's drugs aim at.
Blocking TGF-beta, a cell-communication pathway involved in tissue repair, brought the pericytes back and cut both scarring and vascular amyloid.
The reversal worked in aged APOE4 mice, not just in lab dishes.
A companion study showed APOE4 also piles cholesterol into astrocytes, disabling their waste disposal and letting alpha-synuclein spread to neurons.
If you carry APOE4 or have watched a parent decline with Alzheimer's, this research explains part of the why. Roughly 7 million older Americans have the disease, and for decades scientists assumed the deterioration of the brain's blood vessels was just collateral damage, a late consequence of the illness.
Two new studies from Mount Sinai's Icahn School of Medicine, appearing September 24 in the journals Cell and Cell Stem Cell, show the gene itself does the breaking. The researchers started with postmortem human brain tissue and built a single-cell atlas of gene activity across the brain's vasculature.
In APOE4 carriers, pericytes, the cells that wrap small vessels and maintain the blood-brain barrier, the brain's gatekeeper against circulating proteins, had transformed into myofibroblast-like scar-forming cells. That switch drove vascular fibrosis, a stiffening and thickening of the vessels, and increased amyloid accumulation around them.
Then came the reversal: blocking TGF-beta signaling brought the pericytes back and eased both the fibrosis and the vessel amyloid. The team reproduced the reversal in aged APOE4 mice.
The second study traced a different trail of damage. In miBrains, a lab-grown stand-in for human brain tissue built from stem cells, complete with all major brain cell types plus a vascular network, APOE4 caused cholesterol to accumulate in astrocytes, the brain's support cells.
The excess cholesterol crippled the astrocytes' lysosomes, the waste-disposal units inside cells. With disposal impaired, alpha-synuclein, the protein linked to Parkinson's and Lewy body dementia, clumped and spread into neurons.
"Damage to the brain's blood vessels is not simply a late consequence of Alzheimer's disease; it is a biologically active process caused by APOE4 that may be reversible," said Joel Blanchard, who led both studies.
What this means for you. If you know your APOE4 status from a genetic test, this work names two concrete processes, vascular scarring and cholesterol-clogged waste disposal in support cells, that sit between the gene and the disease. It also hands drug developers specific targets: TGF-beta blockade for the vessels, cholesterol handling and lysosome function in astrocytes for the protein buildup.
The miBrain platform that made the discovery possible can be cryopreserved, which speeds up testing of candidate drugs against a person's own cells.
A word of caution. Every reversal in these studies happened in mice and lab-grown tissue, not in people. No TGF-beta-blocking therapy for Alzheimer's exists, and TGF-beta acts throughout the body in ways unrelated to the brain, so it is not a ready-made drug target.
The miBrain is a model, not a brain, and the timeline from mechanism to medicine in Alzheimer's has rarely been kind.
Why Should You Care?
For decades, the blood vessels were treated as victims of Alzheimer's; now they are a worksite, and the tools aimed at them may one day protect the high-risk among us.
Mount Sinai Health System press release, "Mount Sinai Researchers Identify How APOE4 Gene Damages Brain Blood Vessels in Alzheimer's Disease," September 24, 2026: https://www.mountsinai.org/about/newsroom/2026/mount-sinai-researchers-identify-how-apoe4-gene-damages-brain-blood-vessels-in-alzheimers-disease
Reuters (Nancy Lapid), "Genetic discovery yields clues toward reversal of Alzheimer's brain damage," September 25, 2026: https://www.reuters.com/business/healthcare-pharmaceuticals/genetic-discovery-yields-clues-toward-reversal-alzheimers-brain-damage-2026-09-25/
